We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ergomed Plc | LSE:ERGO | London | Ordinary Share | GB00BN7ZCY67 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1,346.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMERGO
RNS Number : 6627W
Ergomed plc
19 April 2023
Director's Dealing
Guildford, UK - 19 April 2023 : Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announces that on 19 April 2023, Dr Miroslav Reljanović, Executive Chairman of Ergomed, transferred 400,000 ordinary shares of 1p each in the Company ("Ordinary Shares") to a former director of the Company. The transfer took place following an exercise of options under an option agreement dated 5 August 2019 between Dr Reljanović and the former director and the exercise price was 1p per ordinary share.
Following the transfer, Dr Reljanović holds 9,129,297 ordinary shares representing 17.98% of the Company's issued share capital.
The relevant notifications set out below are provided in accordance with the requirements of Article 19 of the UK Market Abuse Regulation.
1 Details of the person discharging managerial responsibilities/person closely associated a) Name Dr Miroslav Reljanović -------------------------------------- ----------------------------------- 2 Reason for the notification --------------------------------------------------------------------------- a) Position/status Executive Chairman -------------------------------------- ----------------------------------- b) Initial notification Initial Notification /Amendment -------------------------------------- ----------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor --------------------------------------------------------------------------- a) Name Ergomed plc -------------------------------------- ----------------------------------- b) Legal Entity 213800BVS8I9VMC1AP84 Identifier -------------------------------------- ----------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted --------------------------------------------------------------------------- a) Description Ordinary shares of 1 pence each of the financial instrument, type of instrument GB00BN7ZCY67 Identification code -------------------------------------- ----------------------------------- b) Nature of the Transfer of shares transaction -------------------------------------- ----------------------------------- c) Currency GBP -------------------------------------- ----------------------------------- d) Price(s) and Price(s) Volume(s) volume(s) -------------------------------------- ---------------- ----------------- GBP0.01 400,000 ------------------------------------------------------------ ----------------- e) Aggregated information 400,000 - Aggregated volume GBP0.01 - Price GBP4,000 - Aggregated total -------------------------------------- ----------------------------------- f) Date of the 19 April 2023 transaction -------------------------------------- ----------------------------------- g) Place of the London Stock Exchange, AIM transaction -------------------------------------- -----------------------------------
ENDS
Enquiries:
Ergomed plc Tel: +44 (0) 1483 402 975 Miroslav Reljanović (Executive Chairman) Jonathan Curtain (Chief Financial Officer) Keith Byrne (Senior Vice President, Capital Markets and Strategy) Numis Securities Limited (Nominated Tel: +44 (0) 20 7260 Adviser and Joint Broker) 1000 Freddie Barnfield / Euan Brown / Jack McLaren Peel Hunt Securities Limited (Joint Broker) Tel: +44 (0) 20 7418 James Steel / Dr Christopher Golden 8900 Consilium Strategic Communications Tel: +44 (0) 20 3709 - for UK enquiries 5700 Chris Gardner / Matthew Neal ergomed@consilium-comms.com
About Ergomed plc
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO) and mission-critical regulatory compliance and consulting services under the ADAMAS brand. For further information, visit: http://ergomedplc.com .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHEAPLPFFFDEFA
(END) Dow Jones Newswires
April 19, 2023 02:00 ET (06:00 GMT)
1 Year Ergomed Chart |
1 Month Ergomed Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions